[1]
|
WHO (n.d.) Globocan 2020. https://gco.iarc.fr/today/data/factsheets/populations/160-china-fact-sheets
|
[2]
|
Chi-arello, M.M., Fico, V., Pepe, G., et al. (2022) Early Gastric Cancer: A Challenge in Western Countries. World Journal of Gastroenterology, 28, 693-703. https://doi.org/10.3748/wjg.v28.i7.693
|
[3]
|
Correa, P. (2013) Gastric Cancer: Overview. Gastroenterology Clinics of North America, 42, 211-217.
https://doi.org/10.1016/j.gtc.2013.01.002
|
[4]
|
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., et al. (2010) Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Ad-vanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. Lancet, 376, 687-697.
https://doi.org/10.1016/S0140-6736(10)61121-X
|
[5]
|
Joshi, S.S. and Badgwell, B.D. (2021) Current Treatment and Recent Progress in Gastric Cancer. CA: A Cancer Journal for Clinicians, 71, 264-279. https://doi.org/10.3322/caac.21657
|
[6]
|
Lordick, F., Kang, Y.-K., Chung, H.C., et al. (2013) Capecitabine and Cis-platin with or without Cetuximab for Patients with Previously Untreated Advanced Gastric Cancer (EXPAND): A Ran-domised, Open-Label Phase 3 Trial. The Lancet Oncology, 14, 490-499. https://doi.org/10.1016/S1470-2045(13)70102-5
|
[7]
|
潘云枫, 刘宝瑞, 魏嘉. HER2阳性胃癌免疫治疗的研究进展[J]. 中国肿瘤生物治疗杂志, 2021, 28(1): 90-96.
|
[8]
|
刘辉, 施俊. 晚期胃癌治疗的研究进展[J]. 现代肿瘤医学, 2021, 29(23): 4226-4229.
|
[9]
|
Chung, H.C., Bang, Y.J., Fuchs, C.S., et al. (2021) First-Line Pembroli-zumab/Placebo plus Trastuzumab and Chemotherapy in HER2-Positive Advanced Gastric Cancer: KEYNOTE-811. Fu-ture Medicine, 17, 491-501.
https://doi.org/10.2217/fon-2020-0737
|
[10]
|
Gerson, J.N., Skariah, S., Denlinger, C.S. and Astsaturov, I. (2017) Perspectives of HER2-Targeting in Gastric and Esophageal Cancer. Expert Opinion on Investigational Drugs, 26, 531-540.
https://doi.org/10.1080/13543784.2017.1315406
|
[11]
|
Moasser, M.M. (2007) The Oncogene HER2: Its Signaling and Transforming Functions and Its Role in Human Cancer Pathogenesis. Oncogene, 26, 6469-6487. https://doi.org/10.1038/sj.onc.1210477
|
[12]
|
Wu, X., Gu, Z., Chen, Y., et al. (2019) Application of PD-1 Blockade in Cancer Immunotherapy. Computational and Structural Biotechnology Journal, 17, 661-674. https://doi.org/10.1016/j.csbj.2019.03.006
|
[13]
|
Singh, D., Attri, B.K., Gill, R.K. and Bariwal, J. (2016) Review on EGFR Inhibitors: Critical Updates. Mini-Reviews in Medicinal Chemistry, 16, 1134-1166. https://doi.org/10.2174/1389557516666160321114917
|
[14]
|
Meric-Bernstam, F., Johnson, A.M., Dumbrava, E.E.I., et al. (2019) Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. Clinical Cancer Research, 25, 2033-2041.
https://doi.org/10.1158/1078-0432.CCR-18-2275
|
[15]
|
Holbro, T., Beerli, R.R., Maurer, F., et al. (2003) The ErbB2/ErbB3 Heterodimer Functions as an Oncogenic Unit: ErbB2 Requires ErbB3 to Drive Breast Tumor Cell Prolifer-ation. Proceedings of the National Academy of Sciences of the United States of America, 100, 8933-8938. https://doi.org/10.1073/pnas.1537685100
|
[16]
|
Shabbir, A., Qureshi, M.A., Mirza, T. and Khalid, A.B. (2017) Human Epidermal Growth Factor (Her-2) in Gastric and Colorectal Adenocarcinoma. The Journal of Pakistan Medical Association, 67, 1085-1090.
|
[17]
|
Kanayama, K., Imai, H., Usugi, E., et al. (2018) Association of HER2 Gene Amplifi-cation and Tumor Progression in Early Gastric Cancer. Virchows Archiv, 473, 559-565. https://doi.org/10.1007/s00428-018-2433-y
|
[18]
|
Slamon, D.J., Clark, G.M., Wong, S.G., et al. (1987) Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene. Science, 235, 177-182. https://doi.org/10.1126/science.3798106
|
[19]
|
Shitara, K., Yatabe, Y., Matsuo, K., et al. (2013) Prognosis of Patients with Advanced Gastric Cancer by HER2 Status and Trastuzumab Treatment. Gastric Cancer, 16, 261-267. https://doi.org/10.1007/s10120-012-0179-9
|
[20]
|
Yaziji, H., Goldstein, L.C., Barry, T.S., et al. (2004) HER-2 Testing in Breast Cancer Using Parallel Tissue-Based Methods. JAMA, 291, 1972-1977. https://doi.org/10.1001/jama.291.16.1972
|
[21]
|
刘文杰, 吴菡, 黄建, 周武碧. 人类表皮生长因子受体2对胃癌细胞增殖、迁移侵袭和凋亡的影响[J]. 安徽医药, 2021, 25(2): 299-303+426.
|
[22]
|
Gravalos, C. and Jimeno, A. (2008) HER2 in Gastric Cancer: A New Prognostic Factor and a Novel Therapeutic Target. Annals of Oncology, 19, 1523-1529. https://doi.org/10.1093/annonc/mdn169
|
[23]
|
Park, D.I., Yun, J.W., Park, J.H., et al. (2006) HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer. Digestive Diseases and Sciences, 51, 1371-1379. https://doi.org/10.1007/s10620-005-9057-1
|
[24]
|
王龙, 刘巍. 进展期胃癌的分子靶向治疗进展[J]. 临床肿瘤学杂志, 2010, 15(9): 856-860.
|
[25]
|
李龙, 展昊, 龙勃, 等. 曲妥珠单抗联合化疗治疗HER-2阳性晚期胃癌的Meta分析[J]. 中国循证医学杂志, 2017, 17(1): 40-46.
|
[26]
|
沈琳, 徐建明, 冯奉仪, 等. 曲妥珠单抗联合化疗一线治疗人表皮生长因子受体2阳性无法手术的局部进展期或转移性胃或胃食管结合部腺癌的多中心随机对照Ⅲ期临床试验中国亚组报告[J]. 中华肿瘤杂志, 2013, 35(4): 295-300.
|
[27]
|
Wang, F., Liu, T.-S., Yuan, X.-L., et al. (2020) Trastuzumab PLus Docetaxel and Capecitabine as a First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: A Phase II, Multicenter, Open-Label, Single-Arm Study. American Journal of Can-cer Research, 10, 3037-3046.
|
[28]
|
ter Veer, E., van den Ende, T., Creemers, A., et al. (2018) Continuation of Trastuzumab beyond Progression in HER2- Positive Advanced Esophagogastric Cancer: A Meta-Analysis. Acta Onco-logica, 57, 1599-1604.
https://doi.org/10.1080/0284186X.2018.1503421
|
[29]
|
朱逸晖, 李婷, 胡夕春. Trastuzumab deruxtecan的临床研究进展及展望——HER2耐药患者的新希望[J]. 中国癌症杂志, 2021, 31(8): 754-761.
|
[30]
|
程浩, 依荷芭丽•迟, 石素胜. 抗体偶联药物治疗消化系统肿瘤的研究进展[J]. 现代肿瘤医学, 2022, 30(5): 916-922.
|
[31]
|
Okazaki, T. and Honjo, T. (2007) PD-1 and PD-1 Ligands: From Discovery to Clinical Application. International Immunology, 19, 813-824. https://doi.org/10.1093/intimm/dxm057
|
[32]
|
Cui, C., Yu, B., Jiang, Q., et al. (2019) The Roles of PD-1/PD-L1 and Its Signalling Pathway in Gastrointestinal Tract Cancers. Clinical and Experimental Pharmacology and Physiology, 46, 3-10. https://doi.org/10.1111/1440-1681.13028
|
[33]
|
Pardoll, D.M. (2012) The Blockade of Im-mune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. https://doi.org/10.1038/nrc3239
|
[34]
|
Sliwkowski, M.X., Lofgren, J.A., Lewis, G.D., et al. (1999) Nonclinical Studies Addressing the Mechanism of Action of Trastuzumab (Herceptin). Seminars in Oncology, 26, 60-70.
|
[35]
|
Yamazaki, T., Akiba, H., Iwai, H., et al. (2002) Expression of Programmed Death 1 Ligands by Murine T Cells and APC. The Journal of Immunology, 169, 5538-5545. https://doi.org/10.4049/jimmunol.169.10.5538
|
[36]
|
Lv, H., Lv, G., Chen, C., Zong, Q., Jiang, G., Ye, D., Cui, X., He, Y., Xiang, W., Han, Q., Tang, L., Yang, W. and Wang, H. (2021) NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion. Cell Metabolism, 33, 110-127.e5. https://doi.org/10.1016/j.cmet.2020.10.021
|
[37]
|
Kono, K., Takahashi, A., Ichihara, F., et al. (2002) Impaired An-tibody-Dependent Cellular Cytotoxicity Mediated by Herceptin in Patients with Gastric Cancer. Cancer Research, 62, 5813-5817.
|
[38]
|
Alspach, E., Lussier, D.M. and Schreiber, R.D. (2019) Interferon γ and Its Important Roles in Pro-moting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. Cold Spring Harbor Perspectives in Biology, 11, a028480.
https://doi.org/10.1101/cshperspect.a028480
|
[39]
|
Chaganty, B.K.R., Qiu, S., Gest, A., et al. (2018) Trastuzumab Upregulates PD-L1 as a Potential Mechanism of Trastuzumab Resistance through Engagement of Immune Effector Cells and Stimulation of IFNγ Secretion. Cancer Letters, 430, 47-56. https://doi.org/10.1016/j.canlet.2018.05.009
|
[40]
|
Yamashita, K., Iwatsuki, M., Yasuda-Yoshihara, N., et al. (2021) Trastuzumab Upregulates Programmed Death Ligand-1 Expression through Interaction with NK Cells in Gastric Cancer. British Journal of Cancer, 124, 595-603.
https://doi.org/10.1038/s41416-020-01138-3
|
[41]
|
Iwata, T.N., Ishii, C., Ishida, S., et al. (2018) A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model. Molecular Cancer Therapeutics, 17, 1494-1503.
https://doi.org/10.1038/s41416-020-01138-3
|
[42]
|
Nordstrom, J.L., Gorlatov, S., Zhang, W., et al. (2011) An-ti-Tumor Activity and Toxicokinetics Analysis of MGAH22, an Anti-HER2 Monoclonal Antibody with Enhanced Fcγ Receptor Binding Properties. Breast Cancer Research, 13, Article No. R123. https://doi.org/10.1186/bcr3069
|
[43]
|
Bang, Y.J., Giaccone, G., Im, S.A., et al. (2017) First-in-Human Phase 1 Study of Margetuximab (MGAH22), an Fc-Modified Chimeric Monoclonal Antibody, in Patients with HER2-Positive Advanced Solid Tumors. Annals of Oncology, 28, 855-861. https://doi.org/10.1093/annonc/mdx002
|
[44]
|
Taylor, C., Hershman, D., Shah N, et al. (2007) Augmented HER-2 Specific Immunity during Treatment with Trastuzumab and Chemotherapy. Clinical Cancer Research, 13, 5133-5143.
https://doi.org/10.1158/1078-0432.CCR-07-0507
|
[45]
|
Janjigian, Y.Y., Maron, S.B., Chatila, W.K., et al. (2020) First-Line Pembrolizumab and Trastuzumab in HER2-Positive Oesophageal, Gastric, or Gastro-Oesophageal Junction Cancer: An Open-Label, Single-Arm, Phase 2 Trial. The Lancet Oncology, 21, 821-831. https://doi.org/10.1016/S1470-2045(20)30169-8
|
[46]
|
Strong, V.E. (2018) Progress in Gastric Cancer. Updates in Surgery, 70, 157-159.
https://doi.org/10.1007/s13304-018-0543-3
|
[47]
|
Catenacci, D.V.T., Kang, Y.K., Park, H., et al. (2020) Margetux-imab plus Pembrolizumab in Patients with Previously Treated, HER2-Positive Gastro-Oesophageal Adenocarcinoma (CP-MGAH22-05): A Single-Arm, Phase 1b-2 Trial. The Lancet Oncology, 21, 1066-1076. https://doi.org/10.1016/S1470-2045(20)30326-0
|
[48]
|
Tian, X., Zhu, Q. and Zhang, Z. (2021) Durable Clinical Re-sponse to Immune and Targeted Therapies in an Elderly Man with Synchronous Gastric (HER2+) and Bladder Cancers: Case Report and Literature Review. OncoTargets and Therapy, 14, 3701-3708. https://doi.org/10.2147/OTT.S305039
|